Begin typing your search above and press return to search.
Geert Wilders
access_time 28 Nov 2023 4:50 AM GMT
Cusat tragedy: Let experience be a lesson
access_time 27 Nov 2023 4:00 AM GMT
A Constitution always in the making
access_time 27 Nov 2023 11:43 AM GMT
How long will the ceasefire last?
access_time 25 Nov 2023 5:56 AM GMT
The signal from Silkyara tunnel incident
access_time 24 Nov 2023 5:53 AM GMT
Schools breeding hatred
access_time 14 Sep 2023 10:37 AM GMT
access_time 16 Aug 2023 5:46 AM GMT
A Constitution always in the making
access_time 27 Nov 2023 11:43 AM GMT
Debunking myth of Israel’s existence
access_time 23 Oct 2023 7:01 AM GMT
Homechevron_rightSciencechevron_rightStudy finds new drug...

Study finds new drug combo against high-risk leukaemia

Study finds new drug combo against high-risk leukaemia

Sydney: Acute lymphoblastic leukaemia(ALL) is the most common childhood cancer in the blood and bone marrow that affects white blood cells. Recently, a team of researchers has found what could prove to be a new and effective way to treat particularly this aggressive blood cancer in children.

Children who develop 'high risk' acute lymphoblastic leukaemia, subtypes are often resistant to standard treatments and many of these children die from their disease.

One common type of high-risk acute lymphoblastic leukaemia is 'Philadelphia chromosome-like ALL' (Ph-like ALL), named for its similarity to another type, Ph-positive ALL.

A study published in the journal Leukemia proved that the kinase inhibitor, ruxolitinib worked synergistically with several types of commonly used anticancer drugs, the most effective being glucocorticoids, topoisomerase I and II inhibitors, microtubule targeting agents and antimetabolites.

"We are very encouraged by our results, which suggest we could be on the way to developing a more effective way to treat this cancer in some children," said lead researcher Richard Lock, Professor, Head of the Blood Cancers Theme at Children's Cancer Institute.

Based on their in vitro findings, the researchers then carried out in vivo testing in living models of a disease known as 'patient-derived xenograft models' (PDXs) or 'avatars': mice specially bred to grow leukaemia cells taken from individual patients with CRLF2r Ph-like ALL.

The results showed that the addition of ruxolitinib to a common treatment regimen called VXL (consisting of vincristine, 2dexamethasone and L-asparaginase) enhanced treatment efficacy in two out of three avatars, achieving long-term suppression of leukaemia growth in one of these.

"The enhanced effect of treatment when ruxolitinib was added and the variety of drug classes found to synergize with ruxolitinib in our laboratory, suggest the promising potential for kinase inhibitors in the treatment of Ph-like ALL," said Lock.

(With IANS inputs)

Show Full Article
TAGS:ChildrenAcute lymphoblastic leukaemiablood cancer
Next Story